Skip to main content
 

CMS Decides to Put Treatment Decisions in the Hands of Insurers

Tuesday, August 14, 2018

On August 7, the Centers for Medicare and Medicaid Services (CMS) issued guidance giving Medicare Advantage (MA) plans (private insurance plans approved by Medicare that cover hospital and medical expenses) the option of applying prior authorization and step therapy for physician-administered and other Medicare Part B drugs (effective January 1, 2019) stating that this policy change will lower costs, improve quality of life, and ensure that patients receive the most preferred treatment.

Short-Term, Limited Duration Plans will Harm Patient’s Access to Comprehensive Coverage

Thursday, August 9, 2018

On August 1, 2018, the Administration finalized another policy that will impact access to quality health insurance coverage by expanding the availability of short-term, limited duration (STLD) insurance plans that are not required to cover essential health benefits or pre-existing conditions.

Administration’s New Rule Could Put Patients’ Health Coverage at Risk

Monday, June 25, 2018

Back in January, the Trump Administration proposed a new rule that would expand the availability of Association Health Plans (AHPs) that are exempt from regulations like the 10 essential health benefits (EHBs) set by the Patient Protection and Affordable Care Act (ACA or Obamacare). This week, the Trump Administration released a finalized policy to allow loosely affiliated business to band together as AHPs and offer plans that are not held to many important ACA consumer protections.

Patient Focused Drug Development

Thursday, May 24, 2018

Starting in 2012 the Food and Drug Administration (FDA) began to integrate the patient perspective into the drug development process through their Patient-Focused Drug Development (PFDD) initiative. The patient advocacy community can and should partner with the FDA to ensure that they are measuring the full patient experience in clinical trials to include the physical, social, and emotional impacts of a therapy, and CSC has been working closely with the FDA, and other researchers, to explore ways to do so in a more meaningful way.

New Health Care Options May Not Protect Patients

Wednesday, February 28, 2018

The Trump Administration has proposed several rules outlining new health insurance options that would provide lower cost insurance coverage to consumers. However, the Cancer Support Community (CSC) believes that these plans may not comply with the Affordable Care Act (ACA or Obamacare).

A National Day of Action in the Fight to #SaveCHIP

Wednesday, January 10, 2018

Leading children’s health, medical, and advocacy organizations around the country have designated today, January 10, 2018, as a National Day of Action to #SaveCHIP. Today, take a moment to call or email your federal legislators and ask them to extend current CHIP funding NOW.

Strengthened by Action: Join the Grassroots Network

Wednesday, October 25, 2017

For our 35th anniversary year, as part of our Fall Cancer Awareness campaign, the Cancer Support Community would like to highlight how you can make a difference through advocacy so that you and your loved ones can be “strengthened by action!”

Last Ditch Repeal Efforts Will Harm Cancer Patients

Wednesday, September 20, 2017

Just when we started to hope that the debate over the repeal and replacement of the Affordable Care Act (ACA) was at an end, a new plan to repeal and replace the law has been introduced. Senators Lindsey Graham (R-SC) and Bill Cassidy (R-LA) have introduced a bill that would be devastating to individuals living with chronic illness including those who have been impacted by cancer.

Health Care Reform: What's Next

Wednesday, September 6, 2017

Efforts to repeal and replace the Affordable Care Act (ACA or “Obamacare) have been unsuccessful thus far. Although the House passed the “American Health Care Act” in May, the Senate did not pass their companion bill, the “Better Care Reconciliation Act.” However, efforts to repeal and replace the ACA are far from over, and CSC is concerned that several mechanisms may undermine the ability of individuals to access comprehensive, high-quality, timely, and affordable health care coverage.

FDA Reauthorization Bill a Win for Psychosocial Care

Tuesday, August 29, 2017

On August 17, 2017, the Food and Drug Administration Reauthorization Act of 2017 (FDARA) became law. FDARA is primarily responsible for funding the Food and Drug Administration (FDA) so that the agency can review and approve drugs and devices in a timely manner. It also contains provisions that provide guidance for manufacturers on how they conduct research on the drugs and devices they are developing.

Pages

Authors